Seeking Alpha

Galectin updates fatty liver disease trial, reports Q3 results, shares fall

  • Galectin Therapeutics (GALT -10.7%) drops after reporting Q3 results.
  • The company says "five of the eight patients have been enrolled and infused" in a Phase 1 study of GR-MD-02 in NASH.
  • Data from the first cohort of patients is due early next year assuming "all goes as expected."
  • As of September 30, GALT had $9.7M in cash which the company says should last "into Q3 of 2014." (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: